DISCOVERY AND DEVELOPMENT OF CANCER THERAPEUTICS FOR NEXT PROGRAM — MICHAEL DIFILIPPANTONIO (LEIDOS BIOMEDICAL RESEARCH, INC.)
The mission of NExT is to develop agents that eventually become approved anticancer therapeutics. Numerous interconnected activities need to be successfully completed before an IND can be filed with t
| Project title | DISCOVERY AND DEVELOPMENT OF CANCER THERAPEUTICS FOR NEXT PROGRAM |
|---|---|
| Project number | 75N91019D00024-0-759102200019-1 |
| PI name | MICHAEL DIFILIPPANTONIO |
| Institution | LEIDOS BIOMEDICAL RESEARCH, INC. |
| Funding mechanism | N01 |
| Agency | NCI |
| Award amount | $22.36M |
| Fiscal year | 2022 |
| Project start | 2022-09-09T00:00:00 |
| Project end | 2027-09-08T00:00:00 |
| Abstract | The mission of NExT is to develop agents that eventually become approved anticancer therapeutics. Numerous interconnected activities need to be successfully completed before an IND can be filed with t |
| Key terms | <ALL1><ALL1 gene><ATP phosphohydrolase><ATPase><Acute Lymphoblastic Leukemia Protein 1><Adenosine Tr |
$799/mo
Try GrantRadar →